The findings of the two studies were not unexpected, Mustafa said. “Heterogeneity in medical care is well recognized in ...
Medpage Today on MSN1d
Dupilumab Proves Effective in Chronic Spontaneous UrticariaAdd-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) ...
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...
Barclays analyst Carter Gould assigned a Buy rating to Regeneron (REGN – Research Report) today and set a price target of $1,080.00. The company’s shares closed last Friday at $933.02. According to ...
In the wake of the elimination diets, 38% of the parents reported no improvement in their child’s AD, 35% reported a 25% ...
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...
Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...
Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders might be concerned after seeing the share price drop ...
CENTRAL TRUST Co lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.7% in ...
While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...
On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback